Alnylam Suspends Fitusiran Dosing due to Thrombotic Event
Thursday, September 7, 2017
VIA The Hemophilia Federation of America: Alnylam recently became aware of a fatal serious adverse event (SAE) that occurred in a patient with hemophilia A who was receiving fitusiran in the Phase 2 OLE study. As a result, the Company has suspended dosing in all ongoing fitusiran studies pending further review of the safety event and development of a risk mitigation strategy.
Click here for Alnylam’s full press release link is: Press Release